Clinical trial · Observational
Collecting Tumor Samples From Patients With Gynecological Tumors
Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
NCT00897442CI-TRIAL-00024486completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in the study of cancer.
Conditions
Conditions (86)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Borderline Ovarian Clear Cell Tumor | Borderline Ovarian Clear Cell Tumor | ONTOLOGY_EXACT | 0.98 |
| Borderline Ovarian Serous Tumor | Borderline Ovarian Serous Tumor | ONTOLOGY_EXACT | 0.98 |
| Cervical Adenocarcinoma | Cervical Adenocarcinoma | CURATED_BROADER | 0.80 |
| Cervical Adenosquamous Carcinoma | Cervical Adenosquamous Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Cervical Small Cell Carcinoma | Cervical Small Cell Neuroendocrine Carcinoma | ALIAS | 0.90 |
| Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Cervical Squamous Cell Carcinoma | CURATED_BROADER | 0.80 |
| Childhood Embryonal Rhabdomyosarcoma | Childhood Embryonal Rhabdomyosarcoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ancillary-Correlative (biomarker sampling and analysis)
- description
- Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.
- interventionNames
- Other: Laboratory Biomarker Analysis
Primary outcomes (3)
- measure
- Collection of gynecological tumor specimens and serum from patients at GOG institutions
- timeFrame
- Baseline
- measure
- Create a repository for long-term storage of these specimens
- timeFrame
- Baseline
- measure
- Make available tissue and blood for proposed projects
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria:
* Any of the following:
* Patients who have had gynecologic tissue removed during surgery to diagnosis, treat, monitor, and/or prevent primary, persistent, or recurrent gynecologic cancer of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, meeting at least one of the following criteria:
* Group A: Women who underwent surgery, were diagnosed with a primary gynecologic malignancy of the ovary, cervix, uterine corpus, or vulva, and have primary tumor, normal tissue, and blood available for submission for this protocol
* Patients with ovarian cancer including all stages, grades, and common epithelial cell types
* Invasive cancers and serous and mucinous borderline tumors of low malignant potential are allowed
* At least 1 gram of frozen primary tumor tissue must be submitted for this protocol for patients with FIGO stage III or IV epithelial ovarian cancer
* Patients with an invasive malignancy of the cervix or uterine corpus including all stages, grades, and common cell types
* Patients with squamous cell carcinoma of the vulva
* Group B: Women who underwent surgery and were diagnosed with a rare gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, vulva, a gestational trophoblastic tumor, or a tumor arising in endometriosis, and have tumor tissue available for submission for this protocol
* Patients with a rare gynecologic malignancy of the ovary including malignant germ cell tumors; sex cord-stromal tumors; malignant mixed mesodermal tumors; clear cell, mucinous, small cell, or transitional cell carcinomas; malignant Brenner tumors; or borderline tumors of low malignant potential (except serous and mucinous)
* Patients with a rare gynecologic malignancy of the peritoneum, including primary peritoneal cancer or mesothelioma
* Patients with carcinoma of the fallopian tube
* Patients with a rare gynecologic malignancy of the cervix including verrucous, small cell, clear cell, serous, or adenoid cystic carcinomas; carcinoid tumors; malignant mixed mesodermal tumors; or leiomyosarcoma
* Patients with a rare gynecologic malignancy of the uterine corpus including leiomyosarcoma; malignant mixed mesodermal tumors; endometrial stromal sarcomas; smooth muscle tumors of unknown malignant potential; or clear cell or small cell carcinomas
* Patients with a rare gynecologic malignancy of the vagina including verrucous or clear cell carcinomas; melanoma; embryonal rhabdomyosarcoma; or endodermal sinus tumor
* Patients with a rare gynecologic malignancy of the vulva including verrucous carcinoma; melanoma; aggressive angiomyxoma; sarcoma; malignant Paget's disease; or Bartholin gland carcinoma
* Patients with a gestational trophoblastic tumor
* Patients with a tumor arising in endometriosis
* Group C: Women who underwent prophylactic oophorectomy and have at least 1 gram of ovarian tissue and blood available for submission for this protocol
* Group D: Women who underwent surgery to monitor or treat a persistent or recurrent gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, and have persistent or recurrent tumor, normal tissue, and blood available for submission for this protocol
* Concurrent primary cancers are allowed
* No benign cystic tumors of the ovary, including cystic epithelial tumors and mature cystic teratomas
* Prior cytotoxic chemotherapy allowed
* Prior hormonal therapy allowed
* Prior radiotherapy allowed
* Prior surgery allowed
* No more than 6 weeks after prior surgeryReferences
Publications (0)
Data not yet available
No reference posted for this study.